TAIHO Pharmaceutical Milestones

Corporate History	R & D History
1963 Taiho Pharmaceutical Co., Ltd., established Capital increase to ¥100 million A representative of the 49 distribu-tors nationwide assumes the posi-tion of Director 1965 Capital increase from ¥100 to ¥200 million 1969 License with the Soviet Union to introduce Futraful in Japan 1971 Tokushima Plant opens	1963 Solcoseryl injection (peptic ulcer and cerebrovascular medication) introduced 1964 Tiovita Drink (nutrient tonic) introduced Fructone (fructose injection) introduced 1965 Neophagen injection (antiallergic and liver disease medication) introduced 1967 Fructlact injection(electrolyte infusion) introduced Neophagen tablet (antiallergic and liver disease medication) introduced Fructone M (intracranial and intraocular hypotension) introduced Pelex Granule (cold medicine) introduced Glutamine Granules (peptic ulcer medication) introduced 1968 Kylit injection (Xylitol) introduced Efotinon tablet (circulation improvement medication) introduced 1969 Fladd injection (active vitamin B2) introduced

Corporate History

R & D History

1963

Taiho Pharmaceutical Co., Ltd., established
Capital increase to ¥100 million
A representative of the 49 distribu-tors nationwide assumes the posi-tion of Director

1965

Capital increase from ¥100 to ¥200 million

1969

License with the Soviet Union to introduce Futraful in Japan

1971

Tokushima Plant opens

1963

Solcoseryl injection (peptic ulcer and cerebrovascular medication) introduced

1964

Tiovita Drink (nutrient tonic) introduced
Fructone (fructose injection) introduced

1965

Neophagen injection (antiallergic and liver disease medication) introduced

1967

Fructlact injection(electrolyte infusion) introduced
Neophagen tablet (antiallergic and liver disease medication) introduced
Fructone M (intracranial and intraocular hypotension) introduced
Pelex Granule (cold medicine) introduced
Glutamine Granules (peptic ulcer medication) introduced

1968

Kylit injection (Xylitol) introduced
Efotinon tablet (circulation improvement medication) introduced

1969

Fladd injection (active vitamin B2) introduced

Corporate History	R & D History
1974 Proprietary Medicine Division established 1975 Tiovita Drink introduced through an advertisement strategy 1976 Business alliance formed with Nichiban Co., Ltd., with equity participation by Taiho Pharmaceutical 1977 "Otsuka Amagi Mountain Villa" completed 1978 Business alliance formed with Kotai Kasei Co., Ltd., with equity participation by Taiho Pharmaceutical GMP-compliant injection drug plant completed within the Tokushima Plant; full plant integration also completed 1979 New building for Quality Control Department completed 1980 New research laboratory completed in Tokushima Plant	1974 Futraful injection and capsule (anticancer agent) introduced 1978 Futrafulzupo S zupo (anticancer suppository) introduced Coledes A Granule and tablet (antiinflammatory) introduced 1979 Solmack (crude drug gastrointestinal remedy) introduced Glutathione injection introduced 1980 Futraful E Granule (anticancer agent) introduced Alloask (wound healing agent) introduced 1981 Futraful E capsule and E tablet (anticancer agent) introduced Futraful zupo N (anticancer agent) introduced Kylitmin B (electrolyte supplement) introduced Neopas F (anti-inflammatory and analgesic) introduced Tiovita Hogyokusei (nutrient tonic) introduced Pantocrin S (crude drug combination nutrient 1982 Tiovita Gold (nutrient tonic) introduced Solmack Pain (crude drug-combined gastrointestinal pain remedy) introduced

Corporate History

R & D History

1974

Proprietary Medicine Division established

1975

Tiovita Drink introduced through an advertisement strategy

1976

Business alliance formed with Nichiban Co., Ltd., with equity participation by Taiho Pharmaceutical

1977

"Otsuka Amagi Mountain Villa" completed

1978

Business alliance formed with Kotai Kasei Co., Ltd., with equity participation by Taiho Pharmaceutical
GMP-compliant injection drug plant completed within the Tokushima Plant; full plant integration also completed

1979

New building for Quality Control Department completed

1980

New research laboratory completed in Tokushima Plant

1974

Futraful injection and capsule (anticancer agent) introduced

1978

Futrafulzupo S zupo (anticancer suppository) introduced
Coledes A Granule and tablet (antiinflammatory) introduced

1979

Solmack (crude drug gastrointestinal remedy) introduced
Glutathione injection introduced

1980

Futraful E Granule (anticancer agent) introduced
Alloask (wound healing agent) introduced

1981

Futraful E capsule and E tablet (anticancer agent) introduced
Futraful zupo N (anticancer agent) introduced
Kylitmin B (electrolyte supplement) introduced
Neopas F (anti-inflammatory and analgesic) introduced
Tiovita Hogyokusei (nutrient tonic) introduced
Pantocrin S (crude drug combination nutrient

1982

Tiovita Gold (nutrient tonic) introduced
Solmack Pain (crude drug-combined gastrointestinal pain remedy) introduced

Corporate History	R & D History
1986 Head office moved to Chiyoda-ku, Tokyo State-of-the-art FA Plant completed in Tokushima Tazobactam β-lactamase inhibitor licensed to Lederle (AHP) 1987 Synphar Laboratory established in Alberta, Canada 25th Anniversary Ceremony held in Tokyo and Tokushima 1989 New building completed for Product Formulation Research Laboratory 1990 Drug Discovery Center, Training Center, and Computer Center completed in Saitama Taiho Pharmaceutical purchases equity and participates in management of Shinsen Iyaku Co., Ltd. 1991 Okayama Plant completed 1st Health Forum held in Hanno City, Saitama 1992 30th Anniversary Ceremony held in Tokyo 21st Century Vision "Phoenix 21" New Corporate Song "Smile for Me" released Name of Shinsen Iyaku Co., Ltd. changed to Okayama Taiho Pharmaceutical Co., Ltd.	1983 Mylura (contraceptive film) introduced 1984 UFT (anticancer agent) introduced Alloask D (wound healing agent) introduced Futraful E zupo and E zupo S (anticancer agent) introduced 1985 Peletack Granule (non-aspirin analgesic and antipyretic) introduced 1986 Tokuderm (dermatological medication) introduced Solcoseryl jelly and ointment (peptic ulcer and cerebrovascular medication) introduced Solmack S (crude drug gastrointestinal remedy) introduced 1987 Pantocrin S capsule (crude drug-combination nutrient tonic) introduced Methaderm cream and ointment (dermatological medication) introduced 1988 Haloart (anti-inflammatory) introduced UFT Granule (anticancer agent) introduced 1989 Miridacin capsule (anti-inflammatory) introduced Polycain (antifungal medication) introduced Herzer (cardiovascular medication) introduced 1990 Kenicef intravenous (antibiotic) introduced 1991 Mini Ther (portable thermometer with LCD display) introduced 1992 UFT E Granule (anticancer agent) introduced

Corporate History

R & D History

1986

Head office moved to Chiyoda-ku, Tokyo
State-of-the-art FA Plant completed in Tokushima
Tazobactam β-lactamase inhibitor licensed to Lederle (AHP)

1987

Synphar Laboratory established in Alberta, Canada
25th Anniversary Ceremony held in Tokyo and Tokushima

1989

New building completed for Product Formulation Research Laboratory

1990

Drug Discovery Center, Training Center, and Computer Center completed in Saitama
Taiho Pharmaceutical purchases equity and participates in management of Shinsen Iyaku Co., Ltd.

1991

Okayama Plant completed
1st Health Forum held in Hanno City, Saitama

1992

30th Anniversary Ceremony held in Tokyo
21st Century Vision "Phoenix 21"
New Corporate Song "Smile for Me" released
Name of Shinsen Iyaku Co., Ltd. changed to Okayama Taiho Pharmaceutical Co., Ltd.

1983

Mylura (contraceptive film) introduced

1984

UFT (anticancer agent) introduced
Alloask D (wound healing agent) introduced
Futraful E zupo and E zupo S (anticancer agent) introduced

1985

Peletack Granule (non-aspirin analgesic and antipyretic) introduced

1986

Tokuderm (dermatological medication) introduced
Solcoseryl jelly and ointment (peptic ulcer and cerebrovascular medication) introduced
Solmack S (crude drug gastrointestinal remedy) introduced

1987

Pantocrin S capsule (crude drug-combination nutrient tonic) introduced
Methaderm cream and ointment (dermatological medication) introduced

1988

Haloart (anti-inflammatory) introduced
UFT Granule (anticancer agent) introduced

1989

Miridacin capsule (anti-inflammatory) introduced
Polycain (antifungal medication) introduced
Herzer (cardiovascular medication) introduced

1990

Kenicef intravenous (antibiotic) introduced

1991

Mini Ther (portable thermometer with LCD display) introduced

1992

UFT E Granule (anticancer agent) introduced

Corporate History	R & D History
1993 New building enlarged for welfare completed in Okayama Plant 1994 Solmack's commercial film awarded the Dentsu Prize 1995 Taiho Fine Chemical merges with Taiho Pharmaceutical President Kobayashi awarded the GreenDex Award from the Republic of Latvia 1996 Collaborative research agreement for breast cancer therapeutics signed with SRI International (US) Production of Disopain anti-inflammatory tablets shifted to Yoshitomi Pharmaceutical Industries (renamed Mitsubishi Pharma Corporation, 2001) 1997 New investigational drug plant opens Clinical Research USA Office established in New York 1998 Collaborative research and development agreement for angiogenesis inhibitor signed with Sugen, Inc. (U.S.A.) 1999 Yukio Kobayashi, president of Taiho Pharmaceutical, becomes president of Otsuka Pharmaceutical Co., Ltd. 2000 Yukio Kobayashi becomes advisor to Otsuka Pharmaceutical 2001 Yukio Kobayashi becomes chairman of Taiho Pharmaceutical Toru Usami, previously president of Okayama Taiho Pharmaceutical, becomes president of Taiho Pharmaceutical 2002 "Company History" published in commemoration of the 40th Anniversary Taiho Pharma U.S.A., Inc. established	1993 BUP-4 tablet (for urinary incontinence and frequency) introduced 1994 Miridacin tablet (anti-inflammatory and analgesic) introduced Methaderm lotion (dermatological medication) introduced 1995 IPD capsule (antiallergic) introduced Tiovita Drink 2000 (nutrient tonic) introduced 1996 Sapresta Granule (long-lasting calcium antagonist) introduced 1998 Farnezone gel (anti-inflammatory agent) introduced 1999 TS-1 capsule 20·25 (anticancer agent) introduced Sales rights for Serotoneinjection and tablet (antiemietic) received from Yoshitomi Pharmaceutical Industries (renamed Mitsubishi Pharma Corporation) Myocalm solution (myoclonus remedy) introduced (orphan drug) 2000 New Polycain liquid, cream and spray (antifungal) introduced Zahappu (antipyretic and analgesic cataplasm) introduced Solmack Ichoeki (quasi-drug, crude drug-combined gastrointestinal tonic) introduced Sales rights for Lentinan (anticancer agent) received from Ajinomoto Co., Inc. Protecadin tablet (H2-receptor antagonist) introduced 2001 TS-1 capsule for head and neck cancer additionally approved IPD dry syrup 5% (antiallergic) introduced Harncare, the industry's first OTC product for mild incontinence, introduced 2002 Tiovita Drink 1000 (nutrient tonic) introduced Solmack S Ichoeki introduced

Corporate History

R & D History

1993

New building enlarged for welfare completed in Okayama Plant

1994

Solmack's commercial film awarded the Dentsu Prize

1995

Taiho Fine Chemical merges with Taiho Pharmaceutical
President Kobayashi awarded the GreenDex Award from the Republic of Latvia

1996

Collaborative research agreement for breast cancer therapeutics signed with SRI International (US)
Production of Disopain anti-inflammatory tablets shifted to Yoshitomi Pharmaceutical Industries (renamed Mitsubishi Pharma Corporation, 2001)

1997

New investigational drug plant opens
Clinical Research USA Office established in New York

1998

Collaborative research and development agreement for angiogenesis inhibitor signed with Sugen, Inc. (U.S.A.)

1999

Yukio Kobayashi, president of Taiho Pharmaceutical, becomes president of Otsuka Pharmaceutical Co., Ltd.

2000

Yukio Kobayashi becomes advisor to Otsuka Pharmaceutical

2001

Yukio Kobayashi becomes chairman of Taiho Pharmaceutical
Toru Usami, previously president of Okayama Taiho Pharmaceutical, becomes president of Taiho Pharmaceutical

2002

"Company History" published in commemoration of the 40th Anniversary
Taiho Pharma U.S.A., Inc. established

1993

BUP-4 tablet (for urinary incontinence and frequency) introduced

1994

Miridacin tablet (anti-inflammatory and analgesic) introduced
Methaderm lotion (dermatological medication) introduced

1995

IPD capsule (antiallergic) introduced
Tiovita Drink 2000 (nutrient tonic) introduced

1996

Sapresta Granule (long-lasting calcium antagonist) introduced

1998

Farnezone gel (anti-inflammatory agent) introduced

1999

TS-1 capsule 20·25 (anticancer agent) introduced
Sales rights for Serotoneinjection and tablet (antiemietic) received from Yoshitomi Pharmaceutical Industries (renamed Mitsubishi Pharma Corporation)
Myocalm solution (myoclonus remedy) introduced (orphan drug)

2000

New Polycain liquid, cream and spray (antifungal) introduced
Zahappu (antipyretic and analgesic cataplasm) introduced
Solmack Ichoeki (quasi-drug, crude drug-combined gastrointestinal tonic) introduced
Sales rights for Lentinan (anticancer agent) received from Ajinomoto Co., Inc.
Protecadin tablet (H2-receptor antagonist) introduced

2001

TS-1 capsule for head and neck cancer additionally approved
IPD dry syrup 5% (antiallergic) introduced
Harncare, the industry's first OTC product for mild incontinence, introduced

2002

Tiovita Drink 1000 (nutrient tonic) introduced
Solmack S Ichoeki introduced

Corporate History	R & D History
2003 Taiho Pharmaceutical signs a licensing agreement for co-promotion of morphine formulation with Dainippon Pharmaceutical Co., Ltd. 2004 Taiho Pharmaceutical signs a licensing agreement for new antiemetic Palonosetron with Helsinn Healthcare SA (Switzerland) Data on UFT adjuvant therapy for lung cancer published in world's foremost medical journal (the New England Journal of Medicine) Taiho Pharmaceutical signs a cooperative agreement on oncology with Tokushima University Taiho Pharmaceutical signs a transfer of distributorship agreement for Zenol brand with Mikasa Pharmaceutical 2005 Taiho Pharmaceutical starts collaborative research and development for injection YP-18 with Toyama Chemical Co. Ltd. Taiho Pharmaceutical signs a licensing agreement for anticancer agent Abraxane with American BioSciences Inc. 2006 Taiho Pharmaceutical signs a licensing agreement for hay fever remedies with Meiji Dairies Corporation Taiho Pharmaceutical holds the first Media Oncology Seminar 2007 Annex to the head office completed Taiho Pharmaceutical holds a ceremony for the 45th anniversary of its founding in Tokyo Solid medicine manufacturing plant dedicated to production of anticancer products newly established Data on TS-1 adjuvant therapy for gastric cancer published in medical journal (NEJM) 2008 Taiho Pharmaceutical and Nippon Shinyaku sign basic agreement on the co-development and marketing of the new antipruritic agent, NS-141 in Japan Otsuka Holdings established Results of a phase III trial on combination chemotherapy of TS-1 and cisplatin for advanced gastric cancer (SPIRITS) published in UK medical journal The Lancet Oncology 2009 Taiho Pharmaceutical and aRigen Pharmaceuticals, Inc., sign co-development and marketing agreement for the new ulcer treatment ARH-1029 Taiho Pharmaceutical wins a TRUSTe Contribution Award at the Japan Privacy Summit 2009 Taiho Pharmaceutical and Toray Industries, Inc., start co-development of β3-adrenoceptor agonist, TAC-301 Results of postoperative adjuvant chemotherapy for breast cancer treatment with UFT® (N-SASBC01) published in the US Journal of Clinical Oncology (JOC) Taiho Pharmaceutical and PharmaMar (Spain) enter into a license agreement on anticancer agent, Yondelis® Taiho Pharmaceutical and GlaxoSmithKline strike a basic agreement on the co-promotion of benign prostatic hyperplasia treatment agent, Avolve® Taiho Pharmaceutical acquires Tsukuba Research Institute from Banyu Pharmaceutical Co., Ltd.	2003 Uzel tablet (reduced folic acid formulation) introduced Tiovita Drink Healthy (nutrient tonic) introduced Pelex troche (cold medicine) introduced Solmack EX (crude drug, gastrointestinal remedy) introduced TS-1 capsule additionally approved for colorectal cancer 2004 Viewgel (hydro-gel wound dressing/ protector) introduced TS-1 capsule for lung cancer additionally approved 2005 Zenol xum SX (topical analgesic/anti-inflammatory) introduced TS-1 capsule for inoperative or recurrent breast cancer additionally approved 2006 Zenol xum SX (topical analgesic/anti-inflammatory) introduced TS-1 capsule for pancreatic cancer additionally approved Harncare Jelly, a herbal medicine for mild incontinence and urinary frequency, introduced Solmack Gold (quasi-drug) introduced 2007 Zenol xum introduced TS-1 capsule for biliary tract cancer additionally approved Henseki (herbal medicine) introduced 2008 Production of small-size Uzel 25 mg tablets started in Japan Zosyn (injectable antibiotic) approved Urepearl Plus series (for treatment of dry skin) introduced 2009 Irinotecan Hydrochioride I.V. Infusion 40mg / 100mg “Taiho” approved Herbal gastrointestinal remedy Solmack Plus introduced TS-1 Capsule approved in China and in Singapore

Corporate History

R & D History

2003

Taiho Pharmaceutical signs a licensing agreement for co-promotion of morphine formulation with Dainippon Pharmaceutical Co., Ltd.

2004

Taiho Pharmaceutical signs a licensing agreement for new antiemetic Palonosetron with Helsinn Healthcare SA (Switzerland)
Data on UFT adjuvant therapy for lung cancer published in world's foremost medical journal (the New England Journal of Medicine)
Taiho Pharmaceutical signs a cooperative agreement on oncology with Tokushima University
Taiho Pharmaceutical signs a transfer of distributorship agreement for Zenol brand with Mikasa Pharmaceutical

2005

Taiho Pharmaceutical starts collaborative research and development for injection YP-18 with Toyama Chemical Co. Ltd.
Taiho Pharmaceutical signs a licensing agreement for anticancer agent Abraxane with American BioSciences Inc.

2006

Taiho Pharmaceutical signs a licensing agreement for hay fever remedies with Meiji Dairies Corporation
Taiho Pharmaceutical holds the first Media Oncology Seminar

2007

Annex to the head office completed
Taiho Pharmaceutical holds a ceremony for the 45th anniversary of its founding in Tokyo
Solid medicine manufacturing plant dedicated to production of anticancer products newly established
Data on TS-1 adjuvant therapy for gastric cancer published in medical journal (NEJM)

2008

Taiho Pharmaceutical and Nippon Shinyaku sign basic agreement on the co-development and marketing of the new antipruritic agent, NS-141 in Japan
Otsuka Holdings established
Results of a phase III trial on combination chemotherapy of TS-1 and cisplatin for advanced gastric cancer (SPIRITS) published in UK medical journal The Lancet Oncology

2009

Taiho Pharmaceutical and aRigen Pharmaceuticals, Inc., sign co-development and marketing agreement for the new ulcer treatment ARH-1029
Taiho Pharmaceutical wins a TRUSTe Contribution Award at the Japan Privacy Summit 2009
Taiho Pharmaceutical and Toray Industries, Inc., start co-development of β3-adrenoceptor agonist, TAC-301
Results of postoperative adjuvant chemotherapy for breast cancer treatment with UFT® (N-SASBC01) published in the US Journal of Clinical Oncology (JOC)
Taiho Pharmaceutical and PharmaMar (Spain) enter into a license agreement on anticancer agent, Yondelis®
Taiho Pharmaceutical and GlaxoSmithKline strike a basic agreement on the co-promotion of benign prostatic hyperplasia treatment agent, Avolve®
Taiho Pharmaceutical acquires Tsukuba Research Institute from Banyu Pharmaceutical Co., Ltd.

2003

Uzel tablet (reduced folic acid formulation) introduced
Tiovita Drink Healthy (nutrient tonic) introduced
Pelex troche (cold medicine) introduced
Solmack EX (crude drug, gastrointestinal remedy) introduced
TS-1 capsule additionally approved for colorectal cancer

2004

Viewgel (hydro-gel wound dressing/ protector) introduced
TS-1 capsule for lung cancer additionally approved

2005

Zenol xum SX (topical analgesic/anti-inflammatory) introduced
TS-1 capsule for inoperative or recurrent breast cancer additionally approved

2006

Zenol xum SX (topical analgesic/anti-inflammatory) introduced
TS-1 capsule for pancreatic cancer additionally approved
Harncare Jelly, a herbal medicine for mild incontinence and urinary frequency, introduced
Solmack Gold (quasi-drug) introduced

2007

Zenol xum introduced
TS-1 capsule for biliary tract cancer additionally approved
Henseki (herbal medicine) introduced

2008

Production of small-size Uzel 25 mg tablets started in Japan
Zosyn (injectable antibiotic) approved
Urepearl Plus series (for treatment of dry skin) introduced

2009

Irinotecan Hydrochioride I.V. Infusion 40mg / 100mg “Taiho” approved
Herbal gastrointestinal remedy Solmack Plus introduced
TS-1 Capsule approved in China and in Singapore

[1963-1972]

[1973-1982]

[1983-1992]

[1993-2002]

[2003-]